ADAM-17: A novel therapeutic target for triple negative breast cancer

Annals of Oncology

Volumn 24, Issue 2, 2013, Pages 362-369

  McGowan, P M ^a,b   Mullooly, M ^a,b   Caiazza, F ^a,b   Sukor, S ^a,b   Madden, S F ^c   Maguire, A A ^a,b   Pierce, A ^a,b   McDermott, E W ^b   Crown, J ^a   O'Donovan, N ^c   Duffy, M J ^a,b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

ADAM17; Therapeutics; Triple negative breast cancer

Indexed keywords

AFATINIB; CARBOPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; GEFITINIB; MESSENGER RNA; NERATINIB; PF 548; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNCLASSIFIED DRUG;

ADAM 17 GENE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOGENESIS; CANCER COMBINATION CHEMOTHERAPY; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE LOCATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RECEPTOR DOWN REGULATION; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION; WESTERN BLOTTING;

ADAM PROTEINS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 84873805663     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds279     Document Type: Article

References (43)

1. Perou CM, Sorlie T, Eisen MB et al Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
2. Sorlie T, Perou CM, Tibshirani R et al Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
3. Foulkes WD, Smith IE, Reis-Filho JS Triple-negative breast cancer. N Engl J Med 2010; 363: 1938-1948.
4. Hoadley KA, Weigman VJ, Fan C et al EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics 2007; 8: 258.
5. Hochgrafe F, Zhang L, O'Toole SA et al Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. Cancer Res 2010; 70: 9391-9401.
6. Viale G, Rotmensz N, Maisonneuve P et al Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat 2009; 116: 317-328.
7. Duffy MJ, McKiernan E, O'Donovan N et al Role of ADAMs in cancer formation and progression. Clin Cancer Res 2009; 15: 1140-1144.
8. Kataoka H EGFR ligands and their signaling scissors, ADAMs, as new molecular targets for anticancer treatments. J Dermatol Sci 2009; 56: 148-153.
9. Blobel CP ADAMs: key components in EGFR signalling and development. Nat Rev Mol Cell Biol 2005; 6: 32-43.
10. Merchant NB, Voskresensky I, Rogers CM et al TACE/ADAM-17: a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer. Clin Cancer Res 2008; 14: 1182-1191.
11. Zhang Y, Hegen M, Xu J et al Characterization of (2R, 3S)-2-([[4-(2-butynyloxy) phenyl]sulfonyl]amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-alpha converting enzyme. Int Immunopharmacol 2004; 4: 1845-1857.
12. Irizarry RA, Hobbs B, Collin F et al Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4: 249-264.
13. Maglott D, Ostell J, Pruitt KD et al Entrez Gene: gene-centered information at NCBI. Nucleic Acids Res 2005; 33: D54-D58.
14. Sorlie T, Tibshirani R, Parker J et al Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-8423.
15. Johnson WE, Li C, Rabinovic A Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007; 8: 118-127.
16. McGowan PM, Ryan BM, Hill AD et al ADAM-17 expression in breast cancer correlates with variables of tumor progression. Clin Cancer Res 2007; 13: 2335-2343.
17. Tryfonopoulos D, Walsh S, Collins DM et al Src: a potential target for the treatment of triple-negative breast cancer. Ann Oncol 2011; 22: 2234-2240.
18. Kyula JN, Van Schaeybroeck S, Doherty J et al Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer. Clin Cancer Res 2010; 16: 3378-3389.
19. Hughes L, Malone C, Chumsri S et al Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity. Clin Exp Metastasis 2008; 25: 549-557.
20. Sahin U, Weskamp G, Kelly K et al Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 2004; 164: 769-779.
21. Hashimura T, Yoshida O Soft agar colony formation of mouse epidermal cells during the early phase of two-stage chemically induced carcinogenesis. Jpn J Cancer Res 1985; 76: 321-323.
22. Sahin U, Blobel CP Ectodomain shedding of the EGF-receptor ligand epigen is mediated by ADAM17. FEBS Lett 2007; 581: 41-44.
23. Nielsen TO, Hsu FD, Jensen K et al Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-5374.
24. O'Shaughnessy J, Weckstein DJ, Vukelja SJ et al Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Breast Cancer Res Treat 2007; 106(Suppl 1): S32. Abstract 308.
25. Carey LA, Rugo HS, Marcom PK et al TBCRC 001: EGFR inhibition with cetuximab in metastatic triple negative (basal-like) breast cancer. Breast Cancer Res Treat 2007; 106(Suppl 1): S32. Abstract 307.
26. Baselga J, Gomez P, Awada A et al The addition of cetuximab to cisplatin increases overall response rate (ORR) and progression-free survival (PFS) in metastatic triple-negative breast cancer (TNBC): results of a randomized phase II study (BALI-1). Ann Oncol 2010; 21(Suppl 8): viii96.
27. Duffy MJ, O'Donovan N, Crown J Use of molecular markers for predicting therapy response in cancer patients. Cancer Treat Rev 2011; 37: 151-159.
28. Dong Y, Li A, Wang J et al Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer. Cancer Res 2010; 70: 5465-5474.
29. Xu H, Stabile LP, Gubish CT et al Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Clin Cancer Res 2011; 17: 4425-4438.
30. Horiuchi K, Zhou HM, Kelly K et al Evaluation of the contributions of ADAMs 9, 12, 15, 17, and 19 to heart development and ectodomain shedding of neuregulins beta1 and beta2. Dev Biol 2005; 283: 459-471.
31. Stern DF ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer. J Mammary Gland Biol Neoplasia 2008; 13: 215-223.
32. Bozkulak EC, Weinmaster G Selective use of ADAM10 and ADAM17 in activation of Notch1 signaling. Mol Cell Biol 2009; 29: 5679-5695.
33. Black RA, Rauch CT, Kozlosky CJ et al A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385: 729-733.
34. Moss ML, Jin SL, Becherer JD et al Structural features and biochemical properties of TNF-alpha converting enzyme (TACE). J Neuroimmunol 1997; 72: 127-129.
35. Wang J, Fu L, Gu F et al Notch1 is involved in migration and invasion of human breast cancer cells. Oncol Rep 2011; 26: 1295-1303.
36. Guo S, Liu M, Gonzalez-Perez RR Role of Notch and its oncogenic signaling crosstalk in breast cancer. Biochim Biophys Acta 2011; 1815: 197-213.
37. Sethi G, Sung B, Aggarwal BB TNF: a master switch for inflammation to cancer. Front Biosci 2008; 13: 5094-5107.
38. Wajant H The role of TNF in cancer. Results Probl Cell Differ 2009; 49: 1-15.
39. Fridman JS, Caulder E, Hansbury M et al Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. Clin Cancer Res 2007; 13: 1892-1902.
40. Liu X, Fridman JS, Wang Q et al Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab. Cancer Biol Ther 2006; 5: 648-656.
41. Zhou BB, Peyton M, He B et al Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 2006; 10: 39-50.
42. Newton RC, Bradley EC, Levy RS et al Clinical benefit of INCB7839, a potent and selective ADAM inhibitor, in combination with trastuzumab in patients with metastatic HER2+ breast cancer. J Clin Oncol 2010; 28(Suppl); Absract 3025.
43. Infante J, Burris HA, Lewis N et al A multicenter phase Ib study of the safety, pharmacokinetics, biological activity and clinical efficacy of INCB7839, a potent and selective inhibitor of ADAM10 and ADAM17. Breast Cancer Res Treat 2007; 106 (Suppl): S269.